Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05196815
Other study ID # 2021CAR121
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date March 1, 2024

Study information

Verified date March 2024
Source The Royal Wolverhampton Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators will assess a variety of novel markers of heart strength (contractility) and assess whether they can give a clearer indication of how well patients with weak hearts respond to the TAVI procedure. The investigators will perform a stress echocardiogram prior to each TAVI procedure and measure the global longitudinal strain (GLS) in the left ventricle (LV) heart muscle, a detailed marker of muscle strength. The investigators will then proceed to the TAVI procedure and measure the contractility of the main pumping chamber in the heart before and after giving a very low dose of an adrenaline -like drug (dobutamine). The patient will already have received this short acting drug (at the same and higher doses) during their routine care planning stress echocardiogram.


Description:

In this study the investigators will assess a variety of novel markers of heart strength (contractility) and assess whether they can give a clearer indication of how well patients with weak hearts respond to the TAVI procedure. The investigators will perform a stress echocardiogram prior to each TAVI procedure and measure the global longitudinal strain (GLS) in the left ventricle (LV) heart muscle, a detailed marker of muscle strength. The investigators will then proceed to the TAVI procedure and measure the contractility of the main pumping chamber in the heart before and after giving a very low dose of an adrenaline -like drug (dobutamine). The patient will already have received this short acting drug (at the same and higher doses) during their routine care planning stress echocardiogram. The investigators will also measure the pressure across the aortic valve, known as the trans-aortic gradient, using the pressure wire (PW) and a standard (multipurpose) heart catheter. The investigators will repeat the resting measures (i.e. without pacing or dobutamine) at the end of the procedure to measure the early change in left ventricular contractility and then repeat the echocardiogram immediately and after 3 months to assess the outcome of the TAVI procedure in terms of left ventricular function volume and function


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date March 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Patients presenting symptomatic AS listed for TAVI 2. Native aortic valve disease 3. Ejection fraction </= 40% 4. Mean trans aortic gradient (echo) of <35 mmHg 5. AVA </= 1cm2 6. Able to give written informed consent prior to enrolment in the study 7. No contraindication to study procedures 8. CT scan confirmed severe AS 9. *Able and willing to return to the implanting site for the follow-up visits* Exclusion Criteria: 1. Unable to provide formal written consent 2. Known pseudo-severe AS prior to TAVI 3. Known allergy to agents required for stress echocardiography 4. Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, Nitinol, or sensitivity to contrast media, which cannot be adequately premedicated. * 5. Any clinical contraindication to TAVI procedure This pilot study will be restricted to English speaking subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ultrasound
Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
Procedure:
Catheters
During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
Soft study wire
Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
Radiation:
X-ray
Participants will have chests x-ray when the soft study wire is inserted.
Drug:
Dobutamine
Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes

Locations

Country Name City State
United Kingdom The Royal Wolverhampton NHS Trust Wolverhampton West Midlands

Sponsors (1)

Lead Sponsor Collaborator
The Royal Wolverhampton Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in LV ejection fraction at 3 months compared to pre procedural readings. Change in LV ejection fraction as a percentage 3 months
Primary Change in LV Volume at 3 months compared to pre procedural readings. Change in LV Volume measured by BSA, mL/m2 3 months
Primary Change in global longitudinal strain at 3 months compared to pre procedural readings. Change in global longitudinal strain measured by percentage 3 months
Primary Change in fractional shortening by echocardiography at 3 months compared to pre procedural readings. Change in fractional shortening measured by percentage 3 months
Primary The change in contractility (dP/dT) with low dose dobutamine stress prior to TAVI, measured by invasive Pressure Wire The change in contractility (dP/dT) with low dose dobutamine stress prior to TAVI, measured by invasive Pressure Wire 3 months
Primary The change in aortic trans-valvular gradient with low dose dobutamine stress during TAVI prior to AV treatment. The change in aortic trans-valvular gradient measured by mmHg 3 months
Primary The change in contractility (dP/dT) from pre to post procedure at 3 months. The change in derivative of pressure over time (dP/dT) is measured by the change in pressure per unit time. Measured ventricular pressure provides an indication of the contractility or relaxation of the ventricles of a heart. In this way, the derivative of pressure over time (dP/dt) provides a biphasic signal that can be used to evaluate acute directional changes of contractility 3 months
See also
  Status Clinical Trial Phase
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Active, not recruiting NCT02973126 - Heartflow (AFFECTS) Phase 3
Withdrawn NCT00844935 - Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients N/A
Completed NCT01410487 - Effects of Weight Loss on Cardio-respiratory Function N/A
Withdrawn NCT00807274 - Renal Function in Adults With Congenital Heart Disease. N/A
Withdrawn NCT00468702 - Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial N/A
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Completed NCT03758092 - Cardiovascular Screening in Infants Born Small for Gestational Age
Completed NCT03545672 - Early Identification of Myocardial Impairment in PBC
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Completed NCT04586894 - Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
Completed NCT03826914 - The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults N/A
Not yet recruiting NCT05624255 - Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score N/A
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Completed NCT01820702 - Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation N/A
Recruiting NCT04766203 - Relative Energy Deficiency in Sport Multicenter Study N/A
Completed NCT01811667 - Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations Phase 3
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Completed NCT02616913 - Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects N/A
Completed NCT00901394 - Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia N/A